Citation Impact
Citing Papers
New approaches and procedures for cancer treatment: Current perspectives
2021 Standout
Sex Disparities in Cancer Mortality and Survival
2011
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Transcriptome Analysis of Triple-Negative Breast Cancer Reveals an Integrated mRNA-lncRNA Signature with Predictive and Prognostic Value
2016
Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development
2011
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
2023 Standout
Apoptosis induction by combination of drugs or a conjugated molecule associating non-steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: implication of the tumor suppressor p73
2015
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
2014
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients
2015
Overexpression of factor inhibiting HIF‐1 enhances vessel maturation and tumor growth via platelet‐derived growth factor‐C
2011
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
A view on drug resistance in cancer
2019 StandoutNature
Breast cancer
2016 Standout
Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma
2019 StandoutNobel
Limits to Personalized Cancer Medicine
2016
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Circulating tumour cells and cell-free DNA as tools for managing breast cancer
2013
Liquid biopsy enters the clinic — implementation issues and future challenges
2021
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Head and neck cancer
2008 Standout
Lung Cancer: Epidemiology, Etiology, and Prevention
2011 Standout
Pancreatic cancer
2016 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Cancer immunotherapy via dendritic cells
2012 Standout
Trial watch
2013
Pancreatic Adenocarcinoma
2014 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Personalised medicine and population health: breast and ovarian cancer
2018
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
2017 Standout
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
The DNA damage response and cancer therapy
2012 Nature
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Chronic Obstructive Pulmonary Disease and Lung Cancer: New Molecular Insights
2011
Revolutionizing healthcare: the role of artificial intelligence in clinical practice
2023 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Sex differences in immune responses
2016 Standout
The Hallmarks of Aging
2013 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination
2013
AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection
2016
Biological subtypes of breast cancer: Prognostic and therapeutic implications
2014
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
2019
ROS and the DNA damage response in cancer
2018 Standout
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas
2012 Standout
Radiomics: the bridge between medical imaging and personalized medicine
2017 Standout
Association Between Pharmaceutical Support and Basic Science Research on Erythropoiesis-Stimulating Agents
2010
Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas
2017 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Circulating tumor DNA as a non‐invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types
2014
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Practical Approach to Triple-Negative Breast Cancer
2017
Long Noncoding RNA and Cancer: A New Paradigm
2017 Standout
Identification and transcriptome analysis of erythroblastic island macrophages
2019 StandoutNobel
Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
2010
SomaticTP53Mutations in the Era of Genome Sequencing
2016
Chemotherapy for advanced gastric cancer
2017 Standout
p62/SQSTM 1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer
2016
Nuclear entry and export of FIH are mediated by HIF1α and exportin1, respectively
2018 StandoutNobel
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review
2016
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Do Erythropoietin Receptors on Cancer Cells Explain Unexpected Clinical Findings?
2006
Coumarins and Coumarin-Related Compounds in Pharmacotherapy of Cancer
2020 Standout
Industry sponsorship and research outcome
2017 Standout
Works of Frédéric Commo being referenced
Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology
2013
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK -Rearranged Non–Small Cell Lung Cancer Patients
2017
IGF-1R Targeting Increases the Antitumor Effects of DNA-Damaging Agents in SCLC Model: An Opportunity to Increase the Efficacy of Standard Therapy
2013
Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC
2011
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer
2012
Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort
2013
ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform
2013
Chk1 as a new therapeutic target in triple-negative breast cancer
2014
Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)
2014
Mutation of TP53 and Alteration of p14arf Expression in EGFR- and KRAS-Mutated Lung Adenocarcinomas
2013
Differential Expression of Biomarkers in Men and Women
2009
Changes in Signaling Pathways Induced by Vandetanib in a Human Medullary Thyroid Carcinoma Model, as Analyzed by Reverse Phase Protein Array
2013
Gene expression profiling of non-small-cell lung cancer
2008
Array CGH and DNA Sequencing to Personalize Therapy for Metastatic Breast Cancer: A Prospective National Trial (UNICANCER SAFIR-01)
2012
Expression of Erythropoietin and Erythropoietin Receptor in Non–Small Cell Lung Carcinomas
2005
Rapid and Sensitive p53 Alteration Analysis in Biopsies from Lung Cancer Patients Using a Functional Assay and A Universal Oligonucleotide Array
2004
Array CGH and DNA sequencing to personalize targeted treatment of metastatic breast cancer (MBC) patients (pts): A prospective multicentric trial (SAFIR01).
2013